JPWO2021247748A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021247748A5 JPWO2021247748A5 JP2022574229A JP2022574229A JPWO2021247748A5 JP WO2021247748 A5 JPWO2021247748 A5 JP WO2021247748A5 JP 2022574229 A JP2022574229 A JP 2022574229A JP 2022574229 A JP2022574229 A JP 2022574229A JP WO2021247748 A5 JPWO2021247748 A5 JP WO2021247748A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharma
- acceptable salt
- ceutically acceptable
- racemate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 8
- 239000012453 solvate Substances 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102000001253 Protein Kinase Human genes 0.000 claims 3
- 230000001419 dependent effect Effects 0.000 claims 3
- 108060006633 protein kinase Proteins 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000001435 Thromboembolism Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025207773A JP2026048716A (ja) | 2020-06-02 | 2025-11-28 | キナーゼ阻害剤 |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063033729P | 2020-06-02 | 2020-06-02 | |
| US202063033728P | 2020-06-02 | 2020-06-02 | |
| US202063033724P | 2020-06-02 | 2020-06-02 | |
| US63/033,724 | 2020-06-02 | ||
| US63/033,728 | 2020-06-02 | ||
| US63/033,729 | 2020-06-02 | ||
| US202163136593P | 2021-01-12 | 2021-01-12 | |
| US202163136587P | 2021-01-12 | 2021-01-12 | |
| US202163136577P | 2021-01-12 | 2021-01-12 | |
| US63/136,577 | 2021-01-12 | ||
| US63/136,587 | 2021-01-12 | ||
| US63/136,593 | 2021-01-12 | ||
| PCT/US2021/035509 WO2021247748A1 (en) | 2020-06-02 | 2021-06-02 | Kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025207773A Division JP2026048716A (ja) | 2020-06-02 | 2025-11-28 | キナーゼ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023528421A JP2023528421A (ja) | 2023-07-04 |
| JP2023528421A5 JP2023528421A5 (https=) | 2024-06-10 |
| JPWO2021247748A5 true JPWO2021247748A5 (https=) | 2024-06-10 |
Family
ID=76601840
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574229A Pending JP2023528421A (ja) | 2020-06-02 | 2021-06-02 | キナーゼ阻害剤 |
| JP2025207773A Pending JP2026048716A (ja) | 2020-06-02 | 2025-11-28 | キナーゼ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025207773A Pending JP2026048716A (ja) | 2020-06-02 | 2025-11-28 | キナーゼ阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12448363B2 (https=) |
| EP (1) | EP4157446A1 (https=) |
| JP (2) | JP2023528421A (https=) |
| CN (1) | CN115867346B (https=) |
| AU (1) | AU2021283916A1 (https=) |
| CA (1) | CA3179637A1 (https=) |
| WO (1) | WO2021247748A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021398051A1 (en) | 2020-12-10 | 2023-07-27 | Principia Biopharma Inc. | Crystal form of tolebrutinib, preparation method therefor and use thereof |
| CN117915960A (zh) * | 2021-08-30 | 2024-04-19 | 百时美施贵宝公司 | 可用于布鲁顿酪氨酸激酶的pet成像的化合物 |
| WO2023227080A1 (zh) * | 2022-05-25 | 2023-11-30 | 百极弘烨(南通)医药科技有限公司 | 一种protac化合物、含其的药物组合物及其制备方法和应用 |
| JP2025521510A (ja) * | 2022-06-22 | 2025-07-10 | プリンシピア バイオファーマ インコーポレイテッド | 改変されたｂｔｋ阻害剤の作製方法 |
| CN116284025B (zh) * | 2023-02-20 | 2025-07-04 | 国科大杭州高等研究院 | 一种具有抗癌作用的螺杂环类化合物、药物组合物及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6509838B2 (ja) * | 2013-06-26 | 2019-05-08 | アッヴィ・インコーポレイテッド | Ｂｔｋ阻害薬としての一級カルボキサミド類 |
| EA034931B1 (ru) * | 2014-10-24 | 2020-04-08 | Бристол-Майерс Сквибб Компани | Индолкарбоксамидные соединения |
| SI3209651T1 (sl) * | 2014-10-24 | 2019-12-31 | Bristol-Myers Squibb Company | Derivati karbazola |
-
2021
- 2021-06-02 CN CN202180048117.5A patent/CN115867346B/zh active Active
- 2021-06-02 WO PCT/US2021/035509 patent/WO2021247748A1/en not_active Ceased
- 2021-06-02 EP EP21734730.1A patent/EP4157446A1/en active Pending
- 2021-06-02 AU AU2021283916A patent/AU2021283916A1/en active Pending
- 2021-06-02 JP JP2022574229A patent/JP2023528421A/ja active Pending
- 2021-06-02 US US18/007,705 patent/US12448363B2/en active Active
- 2021-06-02 CA CA3179637A patent/CA3179637A1/en active Pending
-
2025
- 2025-11-28 JP JP2025207773A patent/JP2026048716A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024100974A5 (https=) | ||
| JP2021523200A5 (https=) | ||
| JP2020502268A5 (https=) | ||
| JP2016534148A5 (https=) | ||
| JP2018529650A5 (https=) | ||
| JP2019531279A5 (https=) | ||
| JP2019501927A5 (https=) | ||
| JPWO2021247748A5 (https=) | ||
| JP2019515924A5 (https=) | ||
| JP2021535213A5 (https=) | ||
| JP2020511547A5 (https=) | ||
| RU2010113358A (ru) | Гуанидинсодержащие соединения, применимые в качестве антагонистов мускариновых рецепторов | |
| JP2021520415A5 (https=) | ||
| JPWO2019213445A5 (https=) | ||
| JP2010534669A5 (https=) | ||
| JP2007538042A5 (https=) | ||
| JP2021503522A5 (https=) | ||
| JP2016539917A5 (https=) | ||
| JP2021532183A5 (https=) | ||
| JP2018135516A5 (https=) | ||
| JPWO2020159904A5 (https=) | ||
| JPWO2021071821A5 (https=) | ||
| JPWO2022214691A5 (https=) | ||
| JPWO2019243999A5 (https=) | ||
| JP2020525417A5 (https=) |